287 related articles for article (PubMed ID: 10778956)
1. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Pendyala L; Creaven PJ; Schwartz G; Meropol NJ; Bolanowska-Higdon W; Zdanowicz J; Murphy M; Perez R
Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
Smith PF; Booker BM; Creaven P; Perez R; Pendyala L
J Clin Pharmacol; 2003 Dec; 43(12):1324-8. PubMed ID: 14615468
[TBL] [Abstract][Full Text] [Related]
3. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
Pendyala L; Schwartz G; Smith P; Zdanowicz J; Murphy M; Hausheer F
Cancer Chemother Pharmacol; 2003 May; 51(5):376-84. PubMed ID: 12682786
[TBL] [Abstract][Full Text] [Related]
4. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.
Lauterburg BH; Nguyen T; Hartmann B; Junker E; Küpfer A; Cerny T
Cancer Chemother Pharmacol; 1994; 35(2):132-6. PubMed ID: 7987989
[TBL] [Abstract][Full Text] [Related]
5. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers.
Mulders TM; Keizer ; Ouwerkerk J; van der Velde EA; Breimer DD; Mulder GJ
Clin Cancer Res; 1995 Dec; 1(12):1525-36. PubMed ID: 9815953
[TBL] [Abstract][Full Text] [Related]
6. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
[TBL] [Abstract][Full Text] [Related]
7. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W
J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391
[TBL] [Abstract][Full Text] [Related]
9. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
Olver I; Keefe D; Myers M; Caruso D
Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
13. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Goren MP; Epelman S; Bush DA
Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna.
Meier T; Allenbacher A; Mueller E; Multhoff G; Botzler C; Wiesnet M; Issels R
Anticancer Drugs; 1994 Aug; 5(4):403-9. PubMed ID: 7949243
[TBL] [Abstract][Full Text] [Related]
15. 2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity.
Sood C; O'Brien PJ
Br J Cancer Suppl; 1996 Jul; 27():S287-93. PubMed ID: 8763899
[TBL] [Abstract][Full Text] [Related]
16. Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer.
Malik IA; Mehboobali N; Iqbal MP
Cancer Chemother Pharmacol; 1997; 39(6):561-5. PubMed ID: 9118472
[TBL] [Abstract][Full Text] [Related]
17. The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols.
Di Giuseppe D; Frosali S; Priora R; Di Simplicio FC; Buonocore G; Cellesi C; Capecchi PL; Pasini FL; Lazzerini PE; Jakubowski H; Di Simplicio P
J Lab Clin Med; 2004 Nov; 144(5):235-45. PubMed ID: 15570241
[TBL] [Abstract][Full Text] [Related]
18. Combined intravenous and oral mesna in outpatients treated with ifosfamide.
Goren MP; McKenna LM; Goodman TL
Cancer Chemother Pharmacol; 1997; 40(5):371-5. PubMed ID: 9272112
[TBL] [Abstract][Full Text] [Related]
19. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
Souid AK; Fahey RC; Aktas MK; Sayin OA; Karjoo S; Newton GL; Sadowitz PD; Dubowy RL; Bernstein ML
Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
